Survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A systematic review and discussion of latest controversies.

Abstract

INTRODUCTION:

Peritoneal metastases confer the worst survival amongst all sites of metastatic colorectal cancer. The adoption of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has become an option for patients with isolated colorectal peritoneal metastases (CRPM). The aim of this study was to evaluate the outcomes following CRS and HIPEC for CRPM from published high volume cohort studies and to highlight the latest controversies and future directions of CRPM treatment.

MATERIALS AND METHODS:

A systematic review was performed on published studies on the treatment outcomes of CRS and HIPEC for colorectal peritoneal metastases.

RESULTS:

Twenty studies met the inclusion criteria for the systematic review. The median survival for all patients ranged from 14.6 to 60.1 months. The 5-year overall survival ranged from 23.4% to 52%. For patients with complete cytoreduction, the median survival was 25 to 49 months. Major morbidity and mortality ranged from 15.1% to 47.2% and 0% to 4.5%, respectively.

CONCLUSION:

CRS and HIPEC for the treatment of CRPM is safe and current evidence suggests it improves both median and disease-free survival. However, the efficacy of intraperitoneal chemotherapy, in particular oxaliplatin, has recently come under scrutiny. Accordingly, higher quality evidence is urgently required to contribute to multidisciplinary and international consensus on CRPM treatment strategies.

• Authors: Michael Flood, Vignesh Narasimhan, Peadar Waters, Robert Ramsay, Michael Michael, Satish Warrier, Alexander Heriot
• Journal: The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland (Surgeon) Vol. 19 Issue 5 Pg. 310-320 (Oct 2021) ISSN: 1479-666X [Print] Scotland
• PMID: 33023847 (Publication Type: Journal Article, Review, Systematic Review)
• Copyright: Copyright © 2020 Royal College of Surgeons of Edinburgh (Scottish charity number SC005317) and Royal College of Surgeons in Ireland. Published by Elsevier Ltd. All rights reserved.

Topics

• Colorectal Neoplasms (drug therapy)
• Combined Modality Therapy
• Cytoreduction Surgical Procedures
• Humans
• Hyperthermia, Induced
• Hyperthermic Intraperitoneal Chemotherapy
• Peritoneal Neoplasms (drug therapy)
• Survival Rate